secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107389
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q3 revenue $209.4M (+31% YoY); raises 2025 guidance
-------------------------------------------------------------

- GAAP net income $31.5M ($0.84 diluted EPS); adj. net income $87.3M ($2.25 adj. EPS).
- Record Jornay PM revenue $41.8M; prescriptions up 20% YoY; pain portfolio $167.6M (+11%).
- Full-year 2025 revenue guidance raised to $775-785M; adj. EBITDA guidance $460-470M.
- Ended Q3 with $285.9M cash; Board authorized $150M share repurchase through Dec 2026.
- Adjusted EBITDA $133.0M, up 27% YoY; generated $78.4M cash from operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465925107389/0001104659-25-107389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465925107389/coll-20251106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer